Ameritrade restricts trading of BIEL and HTDS
Recently, I have been conducting some detailed analysis on Bioelectronics Corp ( OTC:BIEL) and HARD TO TREAT DISEASES (PINK:HTDS) . I went to a great length to unravel the potential of rising in price of BIEL and HTDS over the next few months. On BIEL, in particular, I found the stock to be of excellent potential and I decided to increase my holdings by double or even triple the size. However, I hit a wall. Ameritrade simply wouldn’t let me buy the stock. Both, BIEL and HTDS, in my opinion, dropped down, for no good or obvious reason, so such low prices that I deem to be extremely lucrative to open a position in or even increase one’s holdings. Ameritrade simply wouldn’t let me trade.
@@AdsenseRight@@ Initially, I thought that it was a problem with abnormal activity that requires the trader to simly call in and place the stock live with a broker over the phone. No, even that wouldn’t help. Ameritrade simply would NOT allow me to buy. “You could only SELL,” said the representative to me. When I asked for the reason, he said that he had no reason. He told me that Ameritrade simply placed the restriction on these two stocks and would not disclose the reason.
Of course, being an active trader, I have accounts with various popular brokers, such as eTrade and Scottrade for various research purposes but I do not actively use those accounts except for smaller amounts than that which I have with Ameritrade. So, I went ahead and gave it a test with eTrade, and as I expected, my buy orders were fulfilled. I called eTrade and enquired about any questionable activity on BIEL and HTDS’ part, but the representative told me that everything was fine, no problem.
@@CalendarLeft@@Â So, now, bereft of any reasons or explanations, I am left to wonder why Ameritrade, such a major player, one of the most known and largest brokerages, one the biggest stocks trading accounts holder in the United States, a broker that holds more than 6.3 million client accounts totaling more than $300 billion in client assets, is doing that. Why is Ameritrade placing such restrictions on these stocks without any explanation given to the traders.

By Nour Douchi on 12/14/2009 10:37 am PST -- Biotech